Skip to main content
Top
Published in: Inflammation Research 9/2012

01-09-2012 | Short Communication

Switch-associated protein 70 antibodies in multiple sclerosis: relationship between increased serum levels and clinical relapse

Authors: Ece Erdağ, Erdem Tüzün, Elif Uğurel, Filiz Çavuş, Elçin Şehitoğlu, Murat Giriş, Burçak Vural, Mefküre Eraksoy, Gülşen Akman-Demir

Published in: Inflammation Research | Issue 9/2012

Login to get access

Abstract

Objective

To identify an antibody biomarker for multiple sclerosis (MS) that can be used as a predictor of MS relapses.

Methods

MS patients’ sera were screened by a protein macroarray derived from human fetal brain cDNA library (hEX1). Sera of 90 consecutive relapsing remitting MS (RRMS) patients and age-matched 145 Behçet’s disease (BD) patients, 40 infectious meningoencephalitis patients, and 70 healthy controls were screened by ELISA for serum antibodies against the selected clone.

Results

Sequencing of the clone with the highest signal intensity revealed switch-associated protein 70 (SWAP70) as a potential target autoantigen in RRMS. ELISA studies showed high-titer SWAP70-antibodies in 21 (23.3 %) RRMS and 7 (4.8 %) BD patients. SWAP70 antibodies were more likely to be found positive in sera obtained during or shortly after a relapse.

Conclusion

Detection of SWAP70 antibodies during the attack period might suggest that SWAP70 is involved in MS relapse pathogenesis. Whether serum SWAP70 antibody detection may be utilized as an MS relapse predictor should be tested in prospective studies.
Literature
1.
go back to reference Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006;59:880–92.PubMedCrossRef Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006;59:880–92.PubMedCrossRef
2.
go back to reference Vural B, Uğurel E, Tüzün E, Kürtüncü M, Zuliani L, Cavuş F, Içöz S, Erdağ E, Gül A, Güre AO, Vincent A, Ozbek U, Eraksoy M, Akman-Demir G. Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet’s disease. J Neuroimmunol. 2011;239:91–7.PubMedCrossRef Vural B, Uğurel E, Tüzün E, Kürtüncü M, Zuliani L, Cavuş F, Içöz S, Erdağ E, Gül A, Güre AO, Vincent A, Ozbek U, Eraksoy M, Akman-Demir G. Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet’s disease. J Neuroimmunol. 2011;239:91–7.PubMedCrossRef
3.
go back to reference Vural B, Demirkan A, Ugurel E, Kalaylioglu-Wheeler Z, Esen BA, Gure AO, Gül A, Ozbek U. Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet’s disease. Clin Exp Rheumatol. 2009;27:S67–72.PubMed Vural B, Demirkan A, Ugurel E, Kalaylioglu-Wheeler Z, Esen BA, Gure AO, Gül A, Ozbek U. Seroreactivity against PTEN-induced putative kinase 1 (PINK1) in Turkish patients with Behçet’s disease. Clin Exp Rheumatol. 2009;27:S67–72.PubMed
4.
go back to reference Ocaña-Morgner C, Reichardt P, Chopin M, Braungart S, Wahren C, Gunzer M, Jessberger R. Sphingosine 1-phosphate-induced motility and endocytosis of dendritic cells is regulated by SWAP-70 through RhoA. J Immunol. 2011;186:5345–55.PubMedCrossRef Ocaña-Morgner C, Reichardt P, Chopin M, Braungart S, Wahren C, Gunzer M, Jessberger R. Sphingosine 1-phosphate-induced motility and endocytosis of dendritic cells is regulated by SWAP-70 through RhoA. J Immunol. 2011;186:5345–55.PubMedCrossRef
5.
go back to reference Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20:1267–74.PubMedCrossRef Akhter E, Burlingame RW, Seaman AL, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20:1267–74.PubMedCrossRef
Metadata
Title
Switch-associated protein 70 antibodies in multiple sclerosis: relationship between increased serum levels and clinical relapse
Authors
Ece Erdağ
Erdem Tüzün
Elif Uğurel
Filiz Çavuş
Elçin Şehitoğlu
Murat Giriş
Burçak Vural
Mefküre Eraksoy
Gülşen Akman-Demir
Publication date
01-09-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 9/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0488-9

Other articles of this Issue 9/2012

Inflammation Research 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine